# A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

> **NCT02415439** · PHASE1 · COMPLETED · sponsor: **ReveraGen BioPharma, Inc.** · enrollment: 86 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** VBP15
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02415439
- **Lead sponsor:** ReveraGen BioPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-11
- **Final completion:** 2016-05
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2017-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02415439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02415439, "A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02415439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*